Berlex wins Ultravist supply contract:
This article was originally published in Clinica
Berlex Laboratories has been awarded a four-year supply contract with New York Medical Imaging for its Ultravist (iopromide) injectable X-ray contrast agent. The agreement is worth some $6 million over the full period of the agreement. Montville, New Jersey-based Berlex is the US affiliate of German company Schering.
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.